Cartalax (CAS 307297-39-8) is a premium cartilage-specific peptide bioregulator with ≥98% purity (HPLC), designed to target chondrocyte activity and stimulate cartilage regeneration. This pharmaceutical-grade API features a stable peptide structure (Ala-Glu-Asp sequence) and consistent biological activity essential for research and formulation development.
As a cartilage-specific bioregulator, Cartalax influences gene expression related to cartilage matrix synthesis, enhancing Type II collagen production and reducing inflammation in joint tissues. Studies indicate it supports chondrocyte adaptation to stress, slows cartilage degeneration, and accelerates recovery from joint injuries. Ideal for pharmaceutical manufacturers and research institutions developing products for osteoarthritis management, sports medicine, and musculoskeletal health research.
This lyophilized powder formulation ensures stability during storage and easy reconstitution for various applications. Its targeted mechanism provides a more direct approach to cartilage health than conventional joint supplements, making it a valuable raw material for regenerative medicine research and development.
